In vitro carcinogenesis of hamster pancreatic duct cells: cellular and molecular alterations.
Neoplastic transformation of Syrian golden hamster (SGH) pancreatic duct cells was induced by in vitro treatment with the direct-acting carcinogens N-methylnitrosourea (MNU) and N-(2-hydroxypropyl)nitrosourea (HPNU), with subsequent selection by sustained culture in serum- and epidermal growth factor (EGF)-deprived medium. The present study examines the efficacy of serum and EGF deprivation as a selection pressure and the effect of the carcinogen dose, frequency and interval of exposure on tumorigenesis and K-ras mutation. Selection of carcinogen-initiated duct cells by serum and EGF deprivation is highly reproducible and effective, increasing the incidence of tumors from 26 to 93% for MNU or from 0 to 100% for HPNU. SGH pancreatic duct cells exposed to 0.5 mM MNU for 13 weeks (long-treatment schedule) produced K-ras mutations at codon 12 in six of six tumors. However, when cells were exposed to 0.125, 0.25 or 0.5 mM MNU daily for 5 days (short-treatment schedule), mutations of K-ras at codon 13 were identified in four of 16 tumors, the remaining 12 showing no mutations. Duct cells exposed to 0.5 mM HPNU by the short-treatment schedule produced K-ras mutations in codon 13 in six of six tumors, as contrasted to 12 tumors that developed from cells exposed to 0.125 or 0.25 mM HPNU, which all contained K-ras codon 12 mutations. The current experiments demonstrate that K-ras mutation in pancreatic carcinogenesis in vitro by MNU or HPNU can be modified by the nature and dose of the carcinogen as well as the frequency and duration of exposure.
Mangold
K A
KA
Department of Pathology, Northwestern University Medical School, Chicago, IL 60611.
Hubchak
S
S
Mangino
M M
MM
Laconi
S
S
Scarpelli
D G
DG
D000818:Animals; D001483:Base Sequence; D002273:Carcinogens; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002478:Cells, Cultured; D006224:Cricetinae; D015870:Gene Expression; D011905:Genes, ras; D008647:Mesocricetus; D008770:Methylnitrosourea; D008969:Molecular Sequence Data; D009154:Mutation; D009607:Nitrosourea Compounds; D010183:Pancreatic Ducts / Q000187:drug effects* / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology*; D013997:Time Factors; D016211:Transforming Growth Factor alpha / Q000235:genetics
D002273:Carcinogens; D009607:Nitrosourea Compounds; D016211:Transforming Growth Factor alpha; D008770:Methylnitrosourea; C036496:N-(2-hydroxypropyl)-N-nitrosourea